Enkai Pharmaceutical announced the completion of tens of millions of yuan in Series A++ financing, with 3sbio as the lead investor, followed by Zhang Kehe Run, Yijin Capital, and others. The funds raised in this round will be used to accelerate the research and development and clinical trial process of Enkai Pharmaceutical's pipeline products.
恩凯赛药完成数千万元A++轮融资
Enkai Pharmaceutical has completed tens of millions of yuan in Series A++ financing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated